A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus.

Menon M, Blair PA, Isenberg DA, Mauri C. · 2016

Read A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. by Menon M, Blair PA, Isenberg DA, Mauri C. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4803914.txt.

Introduction

Madhvi Menon, Paul A. Blair, David A. Isenberg, and Claudia Mauri uncover a broken peace treaty between two immune cell types in Immunity in 2016. In healthy people, sentinel cells called pDCs coach young B cells into regulatory B cells, which calm immune attack by releasing IL-10. The regulatory cells then rein in the sentinels' own alarm output, closing a feedback loop.

In lupus, the loop fails. Patient sentinel cells pushed B cells toward antibody factories instead of regulators, so the calming cells never formed in proper number. Flooding healthy B cells with the alarm signal copied the fault, and the signal switches inside the cells showed a skewed pattern. In patients who answered to a B-cell drug, both the cell talk and the switch pattern returned to normal.

Catalog record

CREATORMenon M, Blair PA, Isenberg DA, Mauri C.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4803914

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus By Madhvi Menon, Paul A. Blair, David A. Isenberg, Claudia Mauri Published in: Immunity DOI: 10.1016/j.immuni.2016.02.012 ABSTRACT Summary Signals controlling the generation of regulatory B (Breg) cells remain ill-defined. Here we report an “auto”-regulatory feedback mechanism between plasmacytoid dendritic cells (pDCs) and Breg cells. In healthy individuals, pDCs drive the differentiation of CD19+CD24hiCD38hi (immature) B cells into IL-10-producing CD24+CD38hi Breg cells and plasmablasts, via the release of IFN-α and CD40 engagement. CD24+CD38hi Breg cells conversely restrained IFN-α production by pDCs via IL-10 release. In systemic lupus erythematosus (SLE), this cross-talk was compromised; pDCs promoted plasmablast differentiation but failed to induce Breg cells. This defect was recapitulated in healthy B cells upon exposure to a high concentration of IFN-α. Defective pDC-mediated expansion of CD24+CD38hi Breg cell numbers in SLE was associated with altered STAT1 and STAT3 activation. Both altered pDC-CD24+CD38hi Breg cell interactions and STAT1-STAT3 activation were normalized in SLE patients responding to rituximab. We propose that alteration in pDC-CD24+CD38hi Breg cell interaction contributes to the pathogenesis of SLE. INTRODUCTION Regulatory B (Breg) cells exhibit immunosuppressive functions via the release of IL-10, transforming growth factor (TGF)-β, and IL-35 and by induction of other regulatory cells (Mauri and Bosma, 2012, Mauri and Nistala, 2014). In healthy individuals, immature B cells have been shown to regulate T cell responses via the release of IL-10, suppressing T helper 1 (Th1) and Th17 cell differentiation, and by converting effector CD4+ T cells into FoxP3+CD4+ regulatory T (Treg) cells (Blair et al., 2010, Flores-Borja et al., 2013). In several autoimmune diseases, including SLE and rheumatoid arthritis (RA), Breg cells are functionally and numerically impaired (Blair et al., 2010, Flores-Borja et al., 2013). Signals required for the differentiation of human Breg cells remain poorly understood. CD123+BDCA-2+ plasmacytoid dendritic cells (pDCs) are important drivers of innate and adaptive immune responses (McKenna et al., 2005, Reizis et al., 2011). pDCs rapidly produce large amounts of interferon alpha (IFN-α) upon toll-like receptor (TLR) activation during viral infections or in response to neutrophil extracellular traps (NETs) (Gilliet et al., 2008, Hoffmann et al., 2015, Garcia-Romo et al., 2011, Swiecki and Colonna, 2015). In SLE, neutrophils die upon exposure to SLE-derived anti-ribonucleoprotein antibodies and release NETs containing endogenous DNA as well as neutrophil proteins that enter pDC endocytic compartments and activate them to produce high amounts of IFN-α (Garcia-Romo et al., 2011, Lande et al., 2011). IFN-α stimulates multiple cell types, including natural killer (NK) cells, monocytes, myeloid DCs, and T cells, to release a variety of pro-inflammatory cytokines (McKenna et al., 2005). IFN-α produced by pDCs is pivotal in driving the maturation of B cells into plasmablasts (Jego et al., 2003, Poeck et al., 2004). pDCs can induce the differentiation of IL-10-producing T cells and FoxP3+ Treg cells to counterbalance inflammatory responses and to prevent excess inflammation (Ito et al., 2007, Moseman et al., 2004, Swiecki and Colonna, 2015). IFN-α-induced gene signature, together with defects in B cell function, is considered the hallmark of SLE (Bennett et al., 2003, Obermoser and Pascual, 2010). In SLE, chronic activation of pDCs and other cells results in enhanced IFN-α and IFN-α/β receptor (IFN-α/βR) signaling on target cells (Rönnblom and Eloranta, 2013). Higher amounts of IFN-α production in SLE are associated with an accumulation of plasma cells, increased autoantibody, defective apoptotic cell clearance, and promotion of T-cell-dependent inflammation (Li et al., 2015, Pascual et al., 2006). In lupus-prone transgenic mice, transient depletion of pDCs prior to disease initiation reduces autoantibody, type I IFN signature, and kidney pathology compared to undepleted mice (Rowland et al., 2014). Similarly, IFN-α/βR blockade inhibits autoantibody production and protects young lupus-prone BXSB or MRL-Faslpr mice from disease, highlighting a role for pDCs in the disease initiation (Baccala et al., 2012). Furthermore, IRF8-deficient NZB mice, which lack pDCs, display a profound reduction in anti-nuclear, anti-chromatin, and anti-erythrocyte autoantibodies, as well as a significant reduction in kidney disease (Baccala et al., 2013). In addition, mice lacking E2-2, a transcription factor that regulates pDC development, display impaired pDC function, a dramatic reduction in anti-DNA autoantibody production, and glomerulonephritis as well as ameliorated disease (Sisirak et al., 2014). Several studies have linked type I IFNs with an increase in IL-10 production by B cells (Matsumoto et al., 2014, Schubert et al., 2015). However, the role of pDCs and/or type I IFNs in determining whether a B cell becomes a Breg cell or an antibody-producing plasmablast remains unknown. Our data demonstrate that pDCs can generate plasmablasts that co-express IL-10, IL-6, and TNF-α and release antibody, as well as CD24+CD38hi Breg cells. CD24+CD38hi Breg cells provided negative feedback and restrained excessive IFN-α production by pDCs via IL-10 release. In SLE, pDCs failed to induce the differentiation of CD24+CD38hi Breg cells but promoted antibody production. Similarly, in vitro stimulation of healthy B cells with high concentrations of IFN-α failed to expand CD24+CD38hi Breg cells but promoted plasmablast differentiation. In comparison to healthy controls, immature B cells from SLE patients displayed altered STAT1 and STAT3 activation and expressed higher amounts of TNF-α and IL-6 than IL-10. Of note, newly repopulated immature B cells in SLE patients responding to rituximab showed normalized expression of STAT1 and STAT3 and could differentiate into CD24+CD38hi Breg cells. RESULTS pDCs Expand CD24+CD38hi Breg Cells in Healthy Individuals To test whether pDCs could generate Breg cells, as well as plasma cells as previously reported (Jego et al., 2003), we co-cultured negatively isolated healthy B cells with autologous pDCs for 3 days with CpGC, a TLR9 agonist that stimulates both pDCs and B cells (Hartmann et al., 2003). Figures S1A and S1B show the purity of isolated B cells and pDCs. In addition to inducing the differentiation of CD24−CD38hi B cells (plasmablasts), stimulation with pDCs and CpGC induced an expansion of CD24+CD38hi B cells (Figure 1A) (comprising CD24hiCD38hi and CD24intCD38hi B cells as shown in Figure S1C). Of note, both CD24hiCD38hi and CD24intCD38hi B cells were IgMhi, IgDhi, and CD27−, characteristic of B cells at an immature stage of development (Figures S1D). Further phenotypical analysis confirmed that the pDC-expanded plasmablasts were CD27+, IgD−, and IgMlo, whereas pDC-expanded CD24+CD38hi B cells were also CD27−, IgDhi, and IgMhi (Figure 1B). In addition to expanding B cells with an immature phenotype that has previously been associated with Breg cells (Blair et al., 2010), pDCs induced a 4-fold enrichment of IL-10-producing B cells compared to B cells stimulated with CpGC alone (Figure 1C). An expansion of IL-10-producing B cell numbers was observed even at low ratios (up to 1:50 pDCs:B cells) (Figure S1E). Analysis of the co-culture supernatants confirmed significantly increased amounts of IL-10 (Figure 1D). IL-10+ B cells generated by pDCs expressed higher Ki67 than IL-10+ B cells generated on stimulation with CpGC alone (Figure S1F). The majority of IL-10+ B cells induced by pDCs were CD24+CD38hi B cells, with a smaller percentage residing within the plasmablast population, also previously ascribed with regulatory capacity (Figure 1E; Matsumoto et al., 2014). The majority of IL-10+ B cells were CD27−CD38hi B cells, with a smaller percentage found within the CD27+CD38hi population (Figure S1G). CpGC-stimulated pDCs displayed an enhanced ability to expand IL-10+ B cells

Read the complete text